Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 0

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31,641 result(s) found for: 0. Displaying page 1,353 of 1,583.
    «« First « Previous 1349  1350  1351  1352  1353  1354  1355  1356  1357  Next» Last»»
    EudraCT Number: 2012-004577-12 Sponsor Protocol Number: BRF116613 Start Date*: 2015-03-23
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tra...
    Medical condition: patients with metastatic and unresectable stage III or IV melanoma harbouring an activating BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004891-31 Sponsor Protocol Number: FFR110537 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolesc...
    Medical condition: Rhinitis, Allergic, Perennial
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003287-12 Sponsor Protocol Number: CORT125281-601 Start Date*: 2018-02-08
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Phase 1/2a dose-escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of CORT125281 with enzalutamide in patients with metastatic castration-resistant prostate ca...
    Medical condition: Metastatic castration-resistant prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001483-19 Sponsor Protocol Number: MK-3682-021 Start Date*: 2016-01-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects with...
    Medical condition: Hepatitis C infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004158-32 Sponsor Protocol Number: 6096A1-3016 Start Date*: 2015-04-09
    Sponsor Name:Wyeth Pharmaceuticals, Inc. Acting through its division Wyeth Research, a Pfizer Company
    Full Title: PILOT: Characterization of the Prevnar Infant Long-Term Immune Response Versus a Prevnar-Naïve Cohort
    Medical condition: Pneumococcal infection
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003120-36 Sponsor Protocol Number: IMC-C103C-101 Start Date*: 2020-01-03
    Sponsor Name:Immunocore Limited
    Full Title: A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer
    Medical condition: Patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, urothelial carcinoma, ovarian carcinoma and synovial sarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10062006 HLA marker study PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017770 Gastric carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001875-35 Sponsor Protocol Number: 116566 Start Date*: 2019-04-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, open study to assess the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus ...
    Medical condition: Healthy volunteers [Active immunization of infants against gastroenteritis (GE) due to rotavirus (RV)].
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004841-13 Sponsor Protocol Number: VX15-371-101 Start Date*: 2016-08-08
    Sponsor Name:Vertex Pharmaceuticals Inc.
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Ho...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004332-36 Sponsor Protocol Number: DTX-SPL8783-002 Start Date*: 2020-02-01
    Sponsor Name:Starpharma Pty Ltd
    Full Title: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients wit...
    Medical condition: Advanced malignant solid tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-002865-31 Sponsor Protocol Number: CAIN457AIT01 Start Date*: 2014-12-17
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: A 24-week, multicenter, proSpective, open-label stUdy to evaluate the efficacy in terms of non-inferiority with respect to PASI 90 response rate and the safety PRofile of sEcukinuMab 300 mg in Cw6-...
    Medical condition: moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004527-42 Sponsor Protocol Number: W10-664 Start Date*: 2015-02-03
    Sponsor Name:Abbott Laboratories LLC
    Full Title: A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis® in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation.
    Medical condition: Severe Respiratory Syncytial Virus Infection (RSV)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002834-30 Sponsor Protocol Number: 20120328 Start Date*: 2015-07-14
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma
    Medical condition: Unresectable, Stage IIIB to IVM1c Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003985-25 Sponsor Protocol Number: SER150-P-C-001 Start Date*: 2015-06-12
    Sponsor Name:Serodus ASA
    Full Title: Multi-centre, randomized, double-blind, placebo-controlled, phase II study assessing in two sequential cohorts the safety, efficacy and tolerability of a 15 mg BID and a 30 mg BID doses of SER150TB...
    Medical condition: type II diabetic patients with diabetic nephropathy and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10012658 Diabetic complications renal HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000080-16 Sponsor Protocol Number: NeoToc Start Date*: 2016-07-21
    Sponsor Name:Vejle Hospital
    Full Title: Tocotrienol in combination with neoadjuvant chemotherapy for women with breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003605-26 Sponsor Protocol Number: PRO044-CLIN-02 Start Date*: 2014-12-02
    Sponsor Name:Prosensa Therapeutics B.V.
    Full Title: A phase II, open label, extension study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed) SE (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004007-19 Sponsor Protocol Number: AV-007-IM Start Date*: 2006-11-16
    Sponsor Name:Nycomed Austria GmbH
    Full Title: A multi-centre, double-blind, placebo-controlled, randomised, parallel group clinical trial to evaluate efficacy and safety of Actovegin® in diabetic type 2 patients with symptomatic diabetic perip...
    Medical condition: Diabetic Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012685 Diabetic polyneuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001786-34 Sponsor Protocol Number: IT-04-01 Start Date*: 2005-05-16
    Sponsor Name:ALCON ITALIA
    Full Title: Hypotonic efficacy and tollerability of Travoprost in patient with open angle primary glaucoma and/or ocular hypertension, not controlled with dorzolamide + timolol treatment in fixed association...
    Medical condition: Reducing high intraocular pressure in patient with ocular hypertension or open-angle glaucoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10030348 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001065-41 Sponsor Protocol Number: CSET 2006/1205 Start Date*: 2007-04-30
    Sponsor Name:Institut Gustave Roussy
    Full Title: Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors
    Medical condition: refractory or relapsing malignant pediatric solid tumors
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000818-36 Sponsor Protocol Number: 2007/04 Start Date*: 2007-06-19
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: Etude de phase III randomisée comparant deux modes d’administration des facteurs de croissance (G-CSF) non pégylés dans la prévention secondaire des neutropénies sévères
    Medical condition: Tumeurs solides malignes bénéficiant d'un traitement par chimiothérapie selon le schéma J1 = J21
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005646-39 Sponsor Protocol Number: BRTA-0100-016 Start Date*: 2006-01-12
    Sponsor Name:NERVIANO MEDICAL SCIENCES
    Full Title: Phase II exploratory study of brostallicin PNU-166196A in patients with ovarian cancer resistant/refractory to platinum based chemotherapy.
    Medical condition: Advanced/metastatic ovarian cancer resistant or refractory to platinum.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033128 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1349  1350  1351  1352  1353  1354  1355  1356  1357  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 11:53:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA